The preliminary public providing (IPO) of Sai Life Sciences, a outstanding participant in small-molecule drug growth and manufacturing, is scheduled to open on Wednesday, December 11, 2024, and shut on Friday, December 13, 2024. The IPO consists of a contemporary subject price ₹950 crore and a suggestion on the market (OFS) of three.81 crore shares, bringing the full subject dimension to roughly ₹2,940-3,043 crore.
Based in January 1999, Sai Life Sciences Restricted collaborates with main pharmaceutical and biotechnology firms, providing providers in drug discovery, growth, and the manufacturing of small-molecule new chemical entities (NCEs). As a contract analysis, growth, and manufacturing group (CRDMO), the corporate leverages its experience to deal with vital challenges in healthcare.
Sai Life Sciences Financials and Enterprise Overview
In response to the corporate’s Crimson Herring Prospectus (RHP), Sai Life Sciences affords “end-to-end providers throughout the drug discovery, growth, and manufacturing worth chain for small-molecule new chemical entities (NCE).” The corporate works with world pharmaceutical and biotech innovators, boasting over 170 pharmaceutical merchandise in its portfolio, together with 38 merchandise for manufacturing 28 industrial medication.
Disclaimer: The views and proposals made above are these of particular person analysts or broking firms, and never of Mint. We advise buyers to test with licensed consultants earlier than taking any funding selections.
